“In a pivotal 39-week oral repeat dose toxicity study in monkeys, abrocitinib (doses: 0, 15, 35, and 75 mg/kg/day) decreased lymphocytes at all dose levels consistent with its intended pharmacological effect, but had no adverse effects.”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Pivotal GLP studies
6-month rat and 9-month cynomolgus monkey oral studies
“Oral repeat dose toxicity studies in rats (up to 6 months in duration); oral repeat dose toxicity studies in monkeys (up to 9 months in duration)”
✓ VerifiedFDA multi-discipline review, p. 39Source ↗
Route in tox
Oral (gavage)
“A 9-Month Oral Gavage Toxicity and Toxicokinetic Study of PF-04965842 in Cynomolgus Monkeys with a 12-Week Recovery Phase”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗